Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Targeted Oncology
Published in: Targeted Oncology 3/2015

01-09-2015 | Day-to-Day Practice

Regorafenib: start low and go slow

Authors: S. Tabchi, M. Ghosn

Published in: Targeted Oncology | Issue 3/2015

Login to get access

Excerpt

Recent advances in the field of molecular biology have ushered in a new era in the treatment of metastatic colorectal cancer (mCRC). Deeper understanding of tumor biology has allowed for the development of multiple agents that inhibit tumorigenesis through variable mechanisms. A backbone chemotherapy regimen can now be combined with bevacizumab or cetuximab/panitumumab for patients with KRAS/NRAS wild-type tumors [1, 2]. These combinations can be swapped in the second line setting depending on the initial regimen chosen [3]. …
Literature
1.
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines): colon cancer, version 3. 2014
2.
Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K et al (2012) ESMO consensus guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol 23:2479–2516CrossRefPubMed
3.
4.
Grothey A, Van Cutsem E, Sobrero A, CORRECT Study Group et al (2013) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo- controlled, phase 3 trial. Lancet 381(9863):303–312CrossRefPubMed
5.
Wilhelm SM, Dumas J, Adnane L, Lynch M, Carter CA, Schutz G et al (2011) Regorafenib (BAY 73–4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical anti- tumor activity. Int J Cancer 129:245–255CrossRefPubMed
6.
Stein A, Voigt W, Jordan K (2010) Chemotherapy-induced diarrhea: pathophysiology, frequency and guideline-based management. Ther Adv Med Oncol 2(1):51–63PubMedCentralCrossRefPubMed
7.
Benson AB 3rd, Ajani JA, Catalano RB et al (2004) Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol 22(14):2918–2926CrossRefPubMed
8.
Grothey A, George S, van Cutsem E, Blay J-Y, Sobrero A, Demetri GD (2014) Optimizing treatment outcomes with regorafenib: personalized dosing and other strategies to support patient care. Oncologist 19:669–680PubMedCentralCrossRefPubMed
9.
Mross K, Frost A, Steinbild S, Hedbom S, Büchert M, Fasol U et al (2012) A phase I dose-escalation study of regorafenib (BAY 73–4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clin Cancer Res 18:2658–2667CrossRefPubMed
10.
Sunakawa Y, Furuse J, Okusaka T, Ikeda M, Nagashima F, Ueno H et al (2014) Regorafenib in Japanese patients with solid tumors: phase I study of safety, efficacy, and pharmacokinetics. Investig New Drugs 32:104–112CrossRef
Metadata
Title
Regorafenib: start low and go slow
Authors
S. Tabchi
M. Ghosn
Publication date
01-09-2015
Publisher
Springer International Publishing
Published in
Targeted Oncology / Issue 3/2015
Print ISSN: 1776-2596
Electronic ISSN: 1776-260X
DOI
https://doi.org/10.1007/s11523-014-0352-7

Other articles of this Issue 3/2015

Targeted Oncology 3/2015 Go to the issue

Original Research

Targeted delivery of siRNA using transferrin-coupled lipoplexes specifically sensitizes CD71 high expressing malignant cells to antibody-mediated complement attack

Review

Targeting epidermal growth factor receptors and downstream signaling pathways in cancer by phytochemicals

Review

The route to personalized medicine in bladder cancer: where do we stand?

Original Research

Colorectal liver metastases are more often super wild type. Toward treatment based on metastatic site genotyping?

Original Research

Association of drug exposure with toxicity and clinical response in metastatic renal cell carcinoma patients receiving an attenuated dosing regimen of sunitinib

Original Research

Comparison of tyrosine kinase receptors HER2, EGFR, and VEGFR expression in micropapillary urothelial carcinoma with invasive urothelial carcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits